In December 2025, Cosmo Pharmaceuticals reported results from the largest phase III program ever run on a topical treatment for male pattern hair loss. The compound was clascoterone, a topical androgen receptor inhibitor applied straight to the scalp. Interest in clascoterone hair-loss treatment has climbed steeply since then. If it clears regulators, it will be the first genuinely new mechanism for androgenetic alopecia in over 30 years.
What Is Clascoterone?
Clascoterone binds to androgen receptors without activating them. Cosmo Pharmaceuticals developed it, and dermatologists already know the molecule under another name, for a different condition entirely.
The hair loss version is a 5% topical solution applied twice daily. It is not the same product as the 1% acne cream, and the two should never be swapped.
How Does Clascoterone Affect Hair Follicles?
Androgenetic alopecia runs on dihydrotestosterone. DHT binds to androgen receptors inside susceptible hair follicles and shortens each growth phase, so every cycle produces a finer, shorter hair. Eventually nothing visible emerges at all.
Clascoterone reaches those receptors first. DHT still circulates, still arrives at the scalp, and still cannot do anything once it gets there. Two things follow:
- The drug works locally, at the follicle, without shifting hormone levels anywhere else in the body.
- Enzymes in the skin break it down into cortexolone, which is inactive, so very little reaches circulation.
What Is the Link Between Clascoterone and Androgenetic Alopecia?
Every established option works at a distance from the receptor. Finasteride cuts how much DHT the body makes. Minoxidil ignores the hormone altogether and acts on blood supply and follicular cycling instead.
Clascoterone is the first candidate to block the receptor itself in this condition. Whether that makes it safer is a separate question, and nobody has answered it, because receptor blockade has never been tested head-to-head against enzyme inhibition in hair loss.
What Do Clinical Trials Show About Hair Growth?
Two identically designed trials, SCALP-1 and SCALP-2, enrolled 1,465 men across 51 centers in the United States and Europe. Both hit their main hair count endpoint with statistically significant results (p<0.05).
Then the numbers diverge:
- One study reported a 539% relative improvement in target area hair count against placebo.
- The other reported 168% on the same measure.
- On what patients themselves reported, one study reached significance, and one only showed a trend, with the two reaching significance when pooled.
How Safe Is Clascoterone 5% Topical Solution?
Twelve-month data reported in April 2026 showed a safety profile comparable to placebo, with no meaningful systemic endocrine effects. That fits the mechanism. If almost nothing reaches the bloodstream, there is little for it to disturb.
Side effects were mostly local and mild. Drawing on the trial program and several years of the acne formulation in real use, expect:
- Irritation, dryness or redness at the application site
- Mild itching during the first few weeks
- Twice-daily application, indefinitely
That last one is not really a side effect. It is, however, the usual reason people stop. Anyone with a history of scalp dermatitis should flag it before starting, since irritation is what drives most people off a topical. Data beyond 12 months does not yet exist, and the trials recruited men with mild-to-moderate loss rather than advanced cases.
Is Clascoterone FDA Approved?
Yes and no, depending on what you are asking about.
Clascoterone is FDA-approved as Winlevi 1% cream for acne vulgaris in patients aged 12 and older, with approval in August 2020. It was the first genuinely new acne mechanism since 1982. That licence covers facial skin, with one-fifth of the strength being studied for the scalp.
For hair loss, it is approved nowhere. Cosmo has said US and EU submissions follow the twelve-month safety work, with an FDA filing planned for early 2027. Anyone selling it for scalp use today is operating outside an approved indication.
How Does It Compare With Existing Treatment Options?
No head-to-head trial comparing finasteride or minoxidil has been published, so all comparisons below are indirect. With that caveat, patients weighing treatment options can note three things:
- Clascoterone blocks the receptor. Finasteride reduces DHT production. Minoxidil alters follicular blood supply.
- Its systemic exposure appears negligible, whereas oral finasteride lowers circulating DHT throughout the body.
- Gains kept building from month three through month twelve rather than flattening, which is not the usual pattern.
Treatment satisfaction rose 24.5% relative to placebo across the year. Meaningful, though not the transformation the headline percentage implies.
Could Clascoterone Replace a Hair Transplant?
No. The reason is structural rather than pharmacological.
Every drug discussed here defends follicles that are still alive and still cycling. None of them puts a follicle back where one has died, and fibrous tissue has replaced it. Once that has happened, no topical will reverse it.
A hair transplant in Turkey addresses exactly that problem by relocating DHT-resistant follicles from the back of the scalp into thinning regions. At Cosmedica in Istanbul, Dr Levent Acar performs the Micro Sapphire DHI method: grafts are extracted individually, channels are opened with a sapphire blade, and roots are placed using a DHI pen. Smaller channels mean faster healing and better graft survival.
The two approaches handle different stages of the same condition. Surgery replaces what has gone; medication protects what remains.
Conclusion: The Future of Hair Loss Treatment
The clascoterone results are encouraging, and approval would give clinicians a mechanism they have never had. Three things temper that. The two pivotal trials disagreed sharply on effect size, no comparison against established drugs exists, and the drug remains unlicensed for this use.
None of which changes what to do now. Treat early with approved options, keep photographic records, and consider surgery where follicles have already gone. Watch clascoterone. Do not wait for it.
Frequently Asked Questions
When will clascoterone be available for hair loss?
Submissions are in progress. Approval is unlikely before 2027 in either the United States or Europe.
Can I use Winlevi acne cream on my scalp?
No. Different concentration, different placebo, and it was never studied for scalp application.
Does it work for women?
Unknown. The phase III program enrolled men only, and female pattern hair loss has not been assessed in these clinical trials.
How do I judge whether surgery is worth it?
Look at documented outcomes rather than promises. Hair transplant turkey before and after galleries show achievable density, and Turkey hair transplant cost figures are published separately.
Will I need to keep using it permanently?
Almost certainly. Receptor blockade is reversible, so androgen signaling would be expected to resume once treatment stops.
Is clascoterone hair loss treatment stronger than finasteride?
No trial has compared the two, so nobody can answer that yet. The mechanisms differ, and “stronger” is not a meaningful term without head-to-head data.